<DOC>
	<DOCNO>NCT01033448</DOCNO>
	<brief_summary>This open-label , multi-center study evaluate safety tolerability effect viral activity combine PEGASYS COPEGUS extend therapy patient chronic hepatitis C genotype 1 , 2 3 . Patients complete 48 week ( genotype 1 ) 24 week ( genotype 2 3 ) standard treatment PEGASYS COPEGUS identify slow virological responder enrol study order receive additional 24 week treatment . PEGASYS 180 microgram administer sc weekly COPEGUS administer 800 mg , 1000-1200 mg daily oral dos . The anticipated time study treatment 24 week . The target sample size 50-150 patient .</brief_summary>
	<brief_title>A Study Extended Therapy PEGASYS ( Peginterferon Alfa-2a ) Combination With COPEGUS ( Ribavirin ) Patients With Chronic Hepatitis C Slow Response</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis C , Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<criteria>Adult patient &gt; /= 18 year age Chronic hepatitis C , genotype 1 , 2 , 3 Compensated liver disease Patients complete 48 week 24 week standard treatment PEGASYS COPEGUS identify slow virological responder Decompensated liver disease Signs symptoms hepatocellular carcinoma Uncontrolled hypoglycaemia , hyperglycaemia diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>